Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 12, 2017. The report details the presentation of clinical data for GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate, at the 59th annual meeting of the American Society for Hematology (ASH). The filing focuses on GSK's emerging Oncology pipeline following the 2015 divestiture of its commercial Oncology business.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document is a current report focused on clinical trial results and strategic updates rather than financial performance.
Material Changes and Clinical Results
The primary material update concerns the DREAMM-1 study of GSK2857916 in heavily pre-treated relapsed/refractory multiple myeloma patients:
- Response Rate: Monotherapy demonstrated a 60% response rate (95% CI: 42.1% - 76.1%) in a cohort of 35 patients.
- Progression Free Survival: Median progression-free survival was 7.9 months (95% CI: 3.1 - not estimable).
- Patient Profile: 57% of patients had at least five prior lines of treatment; 40% had prior daratumumab treatment.
- Safety Profile: Most common adverse events were corneal events (63%) and thrombocytopenia (57%). No dose-limiting toxicities were reported. Infusion-related reactions occurred in 23% of patients on the first infusion but not on subsequent infusions.
Regulatory milestones include the awarding of Breakthrough Therapy designation by the US FDA and PRIME designation by the European Medicines Agency.
Guidance, Outlook, and Risks
Outlook and Strategy: GSK plans to rapidly progress the development of GSK2857916, initiating pivotal monotherapy studies and new combination studies in 2018. The company has appointed Christine Roth as Oncology Franchise Head to shape commercial and global product strategy.
Novartis Right of First Negotiation (ROFN): The filing clarifies the terms of the ROFN with Novartis regarding GSK's retained early-stage Oncology assets. The ROFN is triggered if GSK seeks a partner, divests, or proposes to seek marketing authorization for specific assets. It does not oblige GSK to sell or partner with Novartis, nor does Novartis hold an "opt-in" or "call" option. The ROFN extends until September 2027.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's Annual Report on Form 20-F for 2016.
Key Facts for Investor Verification
- Verify the timeline for the initiation of pivotal monotherapy and combination studies for GSK2857916 in 2018.
- Confirm the specific terms and triggers of the Novartis Right of First Negotiation (ROFN) regarding future asset commercialization.
- Monitor the long-term safety data regarding corneal events and thrombocytopenia as the trial expands.
- Review the full Annual Report on Form 20-F for 2016 for detailed financial metrics and principal risk factors not included in this current report.